Assembly Biosciences (NASDAQ:ASMB) Announces Quarterly Earnings Results

Assembly Biosciences (NASDAQ:ASMB) posted its earnings results on Thursday. The biopharmaceutical company reported ($0.20) EPS for the quarter, beating the consensus estimate of ($0.72) by $0.52, FiscalAI reports. Assembly Biosciences had a negative return on equity of 4.21% and a negative net margin of 8.98%.The firm had revenue of $13.37 million during the quarter, compared to the consensus estimate of $8.60 million.

Assembly Biosciences Trading Up 10.7%

Shares of ASMB opened at $29.95 on Friday. The stock’s 50-day moving average price is $25.89 and its two-hundred day moving average price is $27.34. Assembly Biosciences has a 12 month low of $20.23 and a 12 month high of $39.71. The company has a market capitalization of $475.91 million, a PE ratio of -272.25 and a beta of 1.10.

Analyst Ratings Changes

Several research firms have recently issued reports on ASMB. Mizuho set a $45.00 price objective on Assembly Biosciences and gave the company an “outperform” rating in a research note on Monday, June 15th. HC Wainwright reiterated a “buy” rating and set a $50.00 target price on shares of Assembly Biosciences in a research report on Monday, May 4th. Guggenheim reiterated a “buy” rating and set a $43.00 target price on shares of Assembly Biosciences in a research report on Thursday, May 28th. Wall Street Zen lowered shares of Assembly Biosciences from a “strong-buy” rating to a “hold” rating in a report on Saturday, May 16th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Assembly Biosciences in a research report on Friday, July 17th. Five analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $44.00.

Hedge Funds Weigh In On Assembly Biosciences

Hedge funds have recently made changes to their positions in the stock. ADAR1 Capital Management LLC increased its position in Assembly Biosciences by 4.2% during the 4th quarter. ADAR1 Capital Management LLC now owns 19,747 shares of the biopharmaceutical company’s stock valued at $672,000 after purchasing an additional 800 shares during the period. OMERS ADMINISTRATION Corp bought a new position in Assembly Biosciences during the 4th quarter worth approximately $530,000. Barclays PLC lifted its position in shares of Assembly Biosciences by 524.6% in the 4th quarter. Barclays PLC now owns 24,741 shares of the biopharmaceutical company’s stock worth $841,000 after purchasing an additional 20,780 shares during the period. Hudson Bay Capital Management LP acquired a new position in shares of Assembly Biosciences in the 4th quarter worth approximately $512,000. Finally, Millennium Management LLC bought a new stake in shares of Assembly Biosciences in the 3rd quarter valued at $553,000. 19.92% of the stock is currently owned by institutional investors.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.